GLP-1 and metabolic research peptides have become one of the most discussed areas in preclinical and clinical science. Compounds that target incretin receptors — including GLP-1, GIP, and glucagon — are studied for their roles in energy homeostasis, adipose tissue biology, and metabolic signalling. This guide covers the key GLP-1 and metabolic research peptides available for laboratory research in the UK, with a focus on Retatrutide and Tirzepatide — two incretin-class compounds that have attracted significant scientific attention in recent years.
What Are GLP-1 and Metabolic Research Peptides?
GLP-1 (glucagon-like peptide-1) is an incretin hormone produced in the gut in response to food intake. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and influences appetite signalling via central nervous system pathways. Research peptides that target the GLP-1 receptor — and related incretin receptors — are studied for their effects on metabolic signalling, energy expenditure, and glucose homeostasis. Like all research peptides, they are supplied strictly for in-vitro and laboratory investigation only.
Retatrutide: GLP-1 Research Peptide with Triple Agonist Mechanism
Retatrutide (LY3437943) is a synthetic peptide that simultaneously activates three receptors — GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon — giving it a broader signalling profile than most incretin-class peptides. Originally developed by Eli Lilly, it has attracted significant scientific interest for its multi-receptor mechanism and the scale of findings emerging from clinical research.
Key research areas include:
- Triple incretin receptor agonism (GLP-1, GIP, glucagon)
- Metabolic signalling and receptor crosstalk research
- Obesity and body weight regulation models
- Type 2 diabetes and insulin resistance research
- NAFLD/NASH research
- Cardiovascular risk factor modulation
- Energy expenditure and thermogenesis pathways
- Comparative incretin receptor pharmacology
The TRIUMPH-1 Phase 3 trial, with topline results published in May 2026, reported a mean body weight reduction of 28.3% at 80 weeks in the highest-dose group, with 45.3% of participants achieving ≥30% weight reduction — outcomes that have generated significant scientific interest in the compound’s receptor-level mechanisms.
Tirzepatide: Dual GLP-1 and GIP Receptor Agonist
Tirzepatide — also known under the brand name Mounjaro — is a synthetic dual agonist peptide that simultaneously targets both GLP-1 and GIP receptors. Developed by Eli Lilly, it represents an important compound in the incretin receptor pharmacology research landscape and has been the subject of extensive clinical investigation through the SURPASS trial programme.
Where Retatrutide targets three receptors (GLP-1, GIP, and glucagon), Tirzepatide targets two — making it a valuable comparator compound for researchers studying the relative contributions of individual incretin receptor pathways to metabolic outcomes.
Key research areas include:
- Dual incretin receptor agonism (GLP-1 and GIP)
- Glucose homeostasis and insulin sensitivity models
- Adipose tissue biology and lipid metabolism research
- Energy balance and appetite signalling pathways
- Comparative incretin pharmacology (dual vs triple agonism)
→ Read the full guide: What Is Tirzepatide (Mounjaro)? UK Research Peptide Guide
GLP-1 Receptor Agonism: What the Research Explores
GLP-1 receptor activation is the most studied incretin pathway in metabolic research. In preclinical and clinical models, GLP-1 receptor agonism has been associated with:
- Glucose-dependent insulin secretion from pancreatic beta cells
- Suppression of glucagon release from alpha cells
- Delayed gastric emptying and reduced food intake signalling
- Central nervous system effects on appetite and satiety
- Cardioprotective effects in cardiovascular disease models
Both Retatrutide and Tirzepatide share this GLP-1 receptor pathway, while their additional receptor targets add complementary dimensions that differentiate them from single agonists and from each other.
GIP Receptor Agonism in Metabolic Research
GIP (glucose-dependent insulinotropic polypeptide) receptor activation enhances insulin secretion and influences adipose tissue metabolism and energy storage. In combination with GLP-1 receptor agonism, GIP activation has been studied for its potential to amplify metabolic effects — a key area of interest in both Retatrutide and Tirzepatide research.
Glucagon Receptor Agonism: The Differentiating Pathway
The glucagon receptor component is what makes Retatrutide particularly distinctive among GLP-1 research peptides. Glucagon receptor activation stimulates hepatic glucose production and increases energy expenditure, potentially enhancing fat oxidation and thermogenesis. This is the pathway that differentiates Retatrutide from dual agonists like Tirzepatide and makes it a compound of particular interest in hepatic metabolism and energy expenditure research.
Retatrutide vs Tirzepatide: Research Differences
Researchers comparing Retatrutide and Tirzepatide will note a key structural difference: Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors, while Retatrutide adds a third — the glucagon receptor. This additional pathway is thought to contribute to greater energy expenditure and hepatic fat reduction in preclinical models. For researchers studying comparative incretin receptor pharmacology, this distinction makes both compounds valuable — either in isolation or in direct comparison.
GLP-1 Research Peptides: Formats Available in the UK
Precision Chain Peptides supplies Retatrutide and Tirzepatide for laboratory research, both UK-dispatched:
- Retatrutide 20mg Vial — lyophilised powder with bacteriostatic water. Retatrutide 20mg Research Peptide
- Retatrutide 20mg Peptide Pen — pen format with precise dosing. Retatrutide 20mg Peptide Pen
- Tirzepatide 20mg Vial — dual GLP-1/GIP agonist, lyophilised, HPLC-verified. Tirzepatide 20mg Research Peptide
All formats are supplied to ≥99% purity, HPLC-verified, with a batch-specific Certificate of Analysis.
Further Reading on GLP-1 and Metabolic Research Peptides
- What Is Tirzepatide (Mounjaro)? UK Research Peptide Guide
- What is Retatrutide? GLP-1 Research Peptide Guide
- Retatrutide 20mg: What Researchers Need to Know
- Retatrutide Peptide Pen: What Researchers Should Check
- Retatrutide vs Semaglutide: What the Research Shows
- What Is GLP-1 and Why Is It a Major Focus of Metabolic Research?
Sourcing GLP-1 Research Peptides in the UK
Researchers looking to source Retatrutide or Tirzepatide in the UK for laboratory use can order directly from Precision Chain Peptides. All GLP-1 and metabolic research peptides are manufactured to ≥99% purity, HPLC-verified, and supplied with a batch-specific Certificate of Analysis. All compounds are dispatched from the UK and are supplied strictly for in-vitro and laboratory research use only.
Browse the full range: Research Peptide Range | Retatrutide 20mg Vial | Retatrutide 20mg Pen | Tirzepatide 20mg
Research Use Only
All compounds supplied by Precision Chain Peptides are strictly for in-vitro and laboratory research use only. They are not intended for human or animal consumption, personal use, or self-administration.
0 comments